VolitionRx Limited (VNRX) Key Metrics
VNRX valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $5.4M
- Enterprise value
- $15.5M
- P/E (TTM)
- —
- Forward P/E
- 20.8
- PEG ratio
- —
- Price / sales
- 2.2
- Price / book
- 38.4 10-yr median 127.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.17
VNRX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsVNRX returns How much profit the business earns on the capital it uses.
Return on assets−142.2 pts
−286.6%
2025 · hover or tap a bar for each year
20162025
Asset turnover+220.9%
0.21
2025 · hover or tap a bar for each year
20162025
VNRX financial health Debt, liquidity and how easily interest is covered.
Net debt+$7.8M
$10.3M
2025 · hover or tap a bar for each year
20162025
Current ratio−67.6%
0.17
2025 · hover or tap a bar for each year
20162025
Interest coverage
-8.5
2025 · hover or tap a bar for each year
20162025
Debt / assets+168.3%
1.66
2025 · hover or tap a bar for each year
20162025
VNRX efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−7 days
45 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue−41.3 pts
5.2%
2025 · hover or tap a bar for each year
20162025
VNRX valuation history
Fiscal year-endToday10-year median
VNRX returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
VNRX debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
VNRX cash returned to shareholders
DividendsBuybacksFree cash flow
VNRX price vs earnings per share
Share price at year-endEPS (right axis)
VNRX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | — | — | — | — | — | — | $3.71B | $1.14B | $1.55B | $2.11B |
| Enterprise value | — | — | — | — | — | — | $3.70B | $1.13B | $1.54B | $2.09B |
| Price / book | — | — | — | — | — | — | 261.6 | 93.6 | 155.8 | 99.5 |
| Earnings yield | — | — | — | — | — | — | −0.4% | −1.6% | −1.0% | −0.6% |
| Free cash flow yield | — | — | — | — | — | — | −0.4% | −1.3% | −0.9% | −0.4% |
| Shareholder yield (dividends + buybacks) | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% |
| Share price at fiscal year-end | $5.11 | $12.00 | $14.34 | $48.60 | $62.80 | $77.80 | $94.80 | $36.20 | $58.80 | $91.40 |
| Per share | ||||||||||
| Revenue per share | — | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | — | — | — | — | — | — | −$0.41 | −$0.57 | −$0.56 | −$0.52 |
| Operating cash flow per share | — | — | — | — | — | — | −$0.33 | −$0.47 | −$0.46 | −$0.39 |
| Free cash flow per share | — | — | — | — | — | — | −$0.34 | −$0.48 | −$0.52 | −$0.41 |
| Cash per share | — | — | — | — | — | — | $0.43 | $0.43 | $0.38 | $0.94 |
| Book value per share | — | — | — | — | — | — | $0.36 | $0.39 | $0.38 | $0.92 |
| Tangible book value per share | — | — | — | — | — | — | $0.35 | $0.37 | $0.36 | $0.89 |
| Capex per share | — | — | — | — | — | — | $0.01 | $0.01 | $0.05 | $0.02 |
| Debt per share | — | — | — | — | — | — | $0.10 | $0.11 | $0.11 | $0.07 |
| Shares outstanding | — | — | — | — | — | — | 39.2M | 31.4M | 26.4M | 23.0M |
| Change in shares outstanding | — | — | — | — | — | — | +24.8% | +18.9% | +14.5% | +30.0% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | — | −156.4% | −133.3% | −122.2% | −163.0% | −94.9% | −87.5% |
| Return on invested capital (ROIC) | — | — | — | — | — | — | −699.0% | −555.5% | −598.7% | — |
| Return on assets (ROA) | −286.6% | −144.4% | −152.7% | −132.2% | −100.0% | −85.8% | −83.0% | −112.2% | −75.1% | −73.4% |
| Return on tangible assets | −354.7% | −296.8% | −126.5% | −166.5% | −98.3% | −78.8% | −77.0% | −105.8% | −105.1% | −49.3% |
| Financial health | ||||||||||
| Total debt | $11.5M | $5.8M | $5.9M | $5.0M | $4.0M | $4.4M | $4.1M | $3.6M | $3.0M | $1.7M |
| Cash & short-term investments | $1.1M | $3.3M | $20.7M | $10.9M | $20.6M | $19.4M | $17.0M | $13.4M | $10.1M | $21.7M |
| Net debt | $10.3M | $2.6M | −$14.9M | −$5.9M | −$16.6M | −$15.0M | −$12.9M | −$9.9M | −$7.2M | −$20.0M |
| Debt / equity | — | — | — | — | 0.22 | 0.27 | 0.29 | 0.29 | 0.30 | 0.08 |
| Debt / assets | 1.66 | 0.62 | 0.21 | 0.27 | 0.15 | 0.17 | 0.19 | 0.20 | 0.20 | 0.07 |
| Current ratio | 0.17 | 0.52 | 2.44 | 0.70 | 3.37 | 3.26 | 4.55 | 5.96 | 4.61 | 10.82 |
| Quick ratio | 0.17 | 0.52 | 2.50 | 0.65 | 3.28 | 3.21 | 4.55 | 5.96 | 4.61 | 10.82 |
| Interest coverage | -8.5 | -79.4 | -162.4 | -183.6 | -181.9 | -163.7 | -126.7 | -161.4 | -205.7 | — |
| Working capital | −$10.2M | −$3.7M | $12.9M | −$5.2M | $15.5M | $14.1M | $13.7M | $11.6M | $8.3M | $20.0M |
| Invested capital | −$23.9M | −$22.4M | −$22.7M | −$8.5M | $1.4M | $1.3M | $1.3M | $2.3M | $2.8M | $1.2M |
| Tangible asset value | −$35.9M | −$26.4M | −$8.7M | −$3.2M | $17.5M | $16.0M | $13.8M | $11.7M | $9.4M | $20.6M |
| Net current asset value | −$40.4M | −$31.5M | −$14.8M | −$9.2M | $12.2M | $10.5M | $10.5M | $8.6M | $5.9M | $18.5M |
| Graham net-net per share | — | — | — | — | — | — | $0.25 | $0.26 | $0.21 | $0.79 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | $1.7M | $180,472 | $130,425 | $346,465 | — | — | — | — |
| Share buybacks (net) | — | $0 | $31,772 | $180,472 | $130,425 | $54,434 | $0 | $0 | $0 | $0 |
| Capex / revenue | 5.2% | 46.5% | 139.8% | 512.5% | 1,081.3% | 14,449.9% | 2,990.6% | — | — | — |
| Capex / depreciation | 0.07 | 0.43 | 0.77 | 1.32 | 0.85 | 1.86 | 0.57 | 0.47 | 2.70 | 1.34 |
| Stock-based compensation / revenue | 100.7% | 102.8% | 295.3% | 1,016.6% | 5,687.4% | 12,844.9% | 8,531.9% | — | — | — |
| R&D / revenue | 583.6% | 1,167.9% | 2,521.8% | 5,004.4% | 14,463.7% | 108,195.2% | 60,618.0% | — | — | — |
| SG&A / revenue | 547.9% | 1,105.8% | 2,182.3% | 5,354.1% | 16,467.3% | 48,682.7% | 32,083.8% | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 45.3 | 52.3 | 74.2 | 50.7 | 39.8 | 193.4 | — | — | — | — |
| Days of inventory on hand | — | — | 34.1 | 212.4 | — | — | — | — | — | — |
| Days payables outstanding | — | 837.7 | 808.6 | 704.2 | — | — | — | 330.5 | 212.9 | 585.9 |
| Cash conversion cycle (days) | — | -785.5 | -700.3 | -441.0 | — | — | — | — | — | — |
| Receivables turnover | 8.06 | 6.98 | 4.92 | 7.20 | 9.17 | 1.89 | — | — | — | — |
| Payables turnover | 0.00 | 0.44 | 0.45 | 0.52 | 0.00 | 0.00 | 0.00 | 1.10 | 1.71 | 0.62 |
| Inventory turnover | — | — | — | 1.72 | 0.00 | 0.00 | — | — | — | — |
| Asset turnover | 0.21 | 0.07 | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $214,191 | $176,596 | $157,613 | $42,560 | $9,814 | $7,118 | — | — | — | — |
| Average payables | $2.8M | $3.0M | $3.1M | $2.3M | $1.5M | $1.1M | $717,208 | $579,448 | $316,457 | $496,670 |
| Average inventory | — | — | $131,775 | $691,644 | $450,772 | $303,178 | — | — | — | — |
| Intangibles / total assets | 4.6% | 3.3% | 0.1% | 0.6% | 0.8% | 1.2% | 1.7% | 2.7% | 3.9% | 2.4% |
Computed from VNRX's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
VNRX valuation and financial ratios
It ended the year with $11.5 million of debt and $1.1 million in cash and short-term investments, net debt of $10.3 million.
See the VNRX income statement, the VNRX chart for price history, or the VNRX stock overview for the latest quote and news.
VNRX key metrics FAQ
How much debt does VolitionRx have?
VolitionRx had total debt of $11.5 million at the end of fiscal 2025.
What is VolitionRx's current ratio?
VolitionRx's current ratio was 0.17 at the end of fiscal 2025: current assets were 0.17 times current liabilities.